Möchten Sie über diese Zeitschrift informiert bleiben? Klicken Sie bitte auf die Buttons, um unsere Alerts zu abonnieren.
Möchten Sie über diese Zeitschrift informiert bleiben? Klicken Sie bitte auf die Buttons, um unsere Alerts zu abonnieren.
Butyrate acts as energy source for intestinal epithelial cells and as key mediator of several immune processes, modulating gene expression mainly through histone deacetylation inhibition. Thanks to these effects, butyrate has been proposed for the treatment of many intestinal diseases. Aim of this study was to investigate the effect of butyrate on the expression of a large series of target genes encoding proteins involved in pro-inflammatory pathways. We performed quantitative real-time-PCR analysis of the expression of 86 genes encoding proteins bearing to pro-inflammatory pathways, before and after butyrate exposure, in primary epithelial cells derived from human small intestine and colon. Butyrate significantly down-regulated the expression of genes involved in inflammatory response, among which nuclear factor kappa beta, interferon-gamma, Toll like 2 receptor and tumour necrosis factor-alpha. Further confirmations of these data, including studies at protein level, would support the use of butyrate as effective therapeutic strategy in intestinal inflammatory disorders.
Kauf
Sofortzugang erwerben (PDF-Download und unbegrenzter Online-Zugang):
Institutszugang
Melden Sie sich mit Open Athens, Shibboleth oder Ihren institutionellen Anmeldedaten an.
Persönliche Anmeldung
Melden Sie sich mit Ihrem brill.com-Konto an
Baronowski, M., 2008. Biological role of liver X receptors. Journal of Physiology and Pharmacology 59: 31-55.
'Biological role of liver X receptors ' () 59 Journal of Physiology and Pharmacology : 31 -55.
Biasi, F., Leonarduzzi, G., Oteiza, P.I. and Poli, G., 2013. Inflammatory bowel disease: mechanisms, redox considerations, and therapeutic targets. Antioxidants and Redox Signaling 19: 1711-1747.
'Inflammatory bowel disease: mechanisms, redox considerations, and therapeutic targets ' () 19 Antioxidants and Redox Signaling : 1711 -1747.
Canani, R.B., Di Costanzo, M., Leone, L., Pedata, M., Meli, R. and Calignano, A., 2011. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World Journal of Gastroenterology 17: 1519-1528.
'Potential beneficial effects of butyrate in intestinal and extraintestinal diseases ' () 17 World Journal of Gastroenterology : 1519 -1528.
Canani, R.B., Terrin, G., Cirillo, P., Castaldo, G., Salvatore, F., Cardillo, G., Cozzuto, A. and Troncone, R., 2004. Butyrate as an effective treatment of congenital chloride diarrea. Gastroenterology 127: 630-634.
'Butyrate as an effective treatment of congenital chloride diarrea ' () 127 Gastroenterology : 630 -634.
Canani, R.B., Terrin, G., Elce, A., Pezzella, V., Heinz-Herian, P., Pedrolli, A., Centenari, C., Amato, F., Tomaiuolo, R., Calignano, A., Troncone, R. and Castaldo, G., 2013. Genotype-dependency of butyrate efficacy in children with congenital chloride diarrhea. Orphanet Journal of Rare Diseases 8: 194.
'Genotype-dependency of butyrate efficacy in children with congenital chloride diarrhea ' () 8 Orphanet Journal of Rare Diseases : 194.
Chen, W.X., Ren, L.H. and Shi, R.H., 2014. Enteric microbiota leads to new therapeutic strategies for ulcerative colitis. World Journal of Gastroenterology 20: 15657-15663.
'Enteric microbiota leads to new therapeutic strategies for ulcerative colitis ' () 20 World Journal of Gastroenterology : 15657 -15663.
Czura, C.J., Wang, H. and Tracey, K.J., 2001. Dual roles for HMGB1: DNA binding and cytokine. Journal of Endotoxin Research 7: 315-321.
'Dual roles for HMGB1: DNA binding and cytokine ' () 7 Journal of Endotoxin Research : 315 -321.
Donohoe, D.R., Collins, L.B., Wali, A., Bigler, A., Sun, W. and Bultman, S.J., 2012. The Warbung effect dictates the mechanism of butyrate mediated histone acetylation and cell proliferation. Molecular Cell 48: 612-626.
'The Warbung effect dictates the mechanism of butyrate mediated histone acetylation and cell proliferation ' () 48 Molecular Cell : 612 -626.
Felice, C., Lewis, A., Armuzzi, A., Lindsay, J.O. and Silver, A., 2015. Selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics 41: 26-38.
'Selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases ' () 41 Alimentary Pharmacology and Therapeutics : 26 -38.
Frank, D.N., St Amand, A.L., Feldman, R.A., Boedeker, E.C., Harpaz, N. and Pace, N.R., 2007. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proceedings of the National Academy of Sciences of the USA 104: 13780-13785.
'Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases ' () 104 Proceedings of the National Academy of Sciences of the USA : 13780 -13785.
Fuyitake, Y., Ohtsuka, Y., Ikuse, T., Ohtani, K., Aoyagi, Y., Fujii, T., Kudo, T., Ishii, M. and Shimizu, T., 2013. Analysis of inflammatory signals in Japanese children with Crohn’s disease. Pediatrics International 55: 753-756.
'Analysis of inflammatory signals in Japanese children with Crohn’s disease ' () 55 Pediatrics International : 753 -756.
Gao, M., Bu, L., Ma, Y. and Liu, D., 2013. Concurrent activation of liver X receptor and peroxisome proliferator-activated receptor alpha exacerbates hepatic steatosis in high fat diet-induced obese mice. PLoS ONE 8: e65641.
'Concurrent activation of liver X receptor and peroxisome proliferator-activated receptor alpha exacerbates hepatic steatosis in high fat diet-induced obese mice ' () 8 PLoS ONE : e65641.
Goncalves, P., Gregorio, I., Caterino, T.A. and Martel, F., 2013. The effect of oxidative stress upon the intestinal epithelial uptake of butyrate. European Journal of Pharmacology 699: 88-100.
'The effect of oxidative stress upon the intestinal epithelial uptake of butyrate ' () 699 European Journal of Pharmacology : 88 -100.
Gorka, P., Pietrzak, P., Kotunia, A., Zabielski, R. and Kowalski, Z.M., 2014. Effect of method of delivery of sodium butyrate on maturation of the small intestine in newborn calves. Journal of Dairy Science 97: 1026-1035.
'Effect of method of delivery of sodium butyrate on maturation of the small intestine in newborn calves ' () 97 Journal of Dairy Science : 1026 -1035.
Guilloteau, P., Martin, L., Eeckhaut, V., Ducatelle, R., Zabielski, R. and Van Immerseel, F., 2010. From the gut to peripheral tissues: the multiple effects of butyrate. Nutrition Research Reviews 23: 366-384.
'From the gut to peripheral tissues: the multiple effects of butyrate ' () 23 Nutrition Research Reviews : 366 -384.
Hamer, H.M., Jonkers, D., Venema, K., Vanhoutvin, S., Troost, F.J. and Brummer, R.J., 2008. Review article: the role of butyrate on colonic function. Alimentary Pharmacology and Therapeutics 27: 104-119.
'Review article: the role of butyrate on colonic function ' () 27 Alimentary Pharmacology and Therapeutics : 104 -119.
Ito, H., Takazoe, M., Fukuda, Y., Hibi, T., Kusugami, K., Andoh, A., Matsumoto, T., Yamamura, T., Azuma, J., Nishimoto, N., Yoshizaki, K., Shimoyama, T. and Kishimoto, T., 2004. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterology 126: 989-996.
'A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease ' () 126 Gastroenterology : 989 -996.
Kimura, R., Takahashi, N., Goto, T., Murota, K. and Kawada, T., 2013. Activation of peroxisome proliferator-activated receptor-alpha (PPARalpha) in proximal intestine improves postprandial lipidemia in obese diabetic KK-Ay mice. Obesity Research and Clinical Practice 7: e353-e360.
'Activation of peroxisome proliferator-activated receptor-alpha (PPARalpha) in proximal intestine improves postprandial lipidemia in obese diabetic KK-Ay mice ' () 7 Obesity Research and Clinical Practice : e353 -e360.
Luhrs, H., Gerke, T., Muller, J.G., Melcher, R., Schauber, J., Boxberge, F., Scheppach, W. and Menzel, T., 2002. Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis. Scandinavian Journal of Gastroenterology 37: 458-466.
'Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis ' () 37 Scandinavian Journal of Gastroenterology : 458 -466.
Mueller, C., 2012. Danger-associated molecular patterns and inflammatory bowel disease: is there a connection? Digestive Diseases 30: 40-46.
'Danger-associated molecular patterns and inflammatory bowel disease: is there a connection? ' () 30 Digestive Diseases : 40 -46.
Ock, C.Y., Kim, E.H., Choi, D.J., Lee, H.J., Hahm, K.B. and Chung, M.H., 2012. 8-hydrozydeoxyguanosine: not mere biomarker for oxidative stress, but remedy for oxidative stress-implicated gastrointestinal diseases. World Journal Gastroenterology 18: 302-308.
'8-hydrozydeoxyguanosine: not mere biomarker for oxidative stress, but remedy for oxidative stress-implicated gastrointestinal diseases ' () 18 World Journal Gastroenterology : 302 -308.
Palumbo, R. and Bianchi, M.E., 2004. High mobility group box 1 protein, a cue for stem cell recruitment. Biochemical Pharmacology 68: 1165-1170.
'High mobility group box 1 protein, a cue for stem cell recruitment ' () 68 Biochemical Pharmacology : 1165 -1170.
Pfaffl, M.W., 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Research 29: 2003-2007.
'A new mathematical model for relative quantification in real-time RT-PCR ' () 29 Nucleic Acids Research : 2003 -2007.
Schenk, M., Bouchon, A., Seibold, F. and Mueller, C., 2007. TREM-1--expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases. Journal of Clinical Investigation 117: 3097-3106.
'TREM-1--expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases ' () 117 Journal of Clinical Investigation : 3097 -3106.
Steppe, M., Van Nieuwerburgh, F., Vercauteren, G., Boyen, F., Eeckhaut, V., Deforce, D., Haesebrouck, F., Ducatelle, R. and Van Immerseel, F., 2014. Safety assessment of the butyrate-producing Butyricicoccus pullicaecorum strain 25-3(T), a potential probiotic for patients with inflammatory bowel disease, based on oral toxicity tests and whole genome sequencing. Food and Chemical Toxicology 72: 129-137.
'Safety assessment of the butyrate-producing Butyricicoccus pullicaecorum strain 25-3(T), a potential probiotic for patients with inflammatory bowel disease, based on oral toxicity tests and whole genome sequencing ' () 72 Food and Chemical Toxicology : 129 -137.
Stojcev, Z., Krokowicz, Ł., Krokowicz, P., Szczepkowski, M., Borycka-Kiciak, K., Kiciak, A. Walkowiak, J., Drews, M. and Banasiewicz, T., 2013. Early treatment and prevention of the radiation proctitis – composite enemas containing sodium butyrate. International Journal of Colorectal Diseases 28: 1731-1732.
'Early treatment and prevention of the radiation proctitis – composite enemas containing sodium butyrate ' () 28 International Journal of Colorectal Diseases : 1731 -1732.
Vitali, R., Stronati, L., Negroni, A., Di Nardo, G., Pierdomenico, M., Del Giudice, E., Rossi, P. and Cucchiara, S., 2011. Fecal HMGB1 is a novel marker of intestinal mucosal inflammation in pediatric inflammatory bowel disease. American Journal of Gastroenterology 106: 2029-2040.
'Fecal HMGB1 is a novel marker of intestinal mucosal inflammation in pediatric inflammatory bowel disease ' () 106 American Journal of Gastroenterology : 2029 -2040.
Waldner, M.J. and Neurath, M.F., 2014. Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development. Seminars in Immunology 26: 75-79.
'Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development ' () 26 Seminars in Immunology : 75 -79.
Wang, L.S., Kuo, C.T., Huang, Y.W., Stoner, G.D. and Lechner, J.F., 2012. Gene-diet interactions on colorectal cancer risk. Current Nutrition Reports 1: 132-141.
'Gene-diet interactions on colorectal cancer risk ' () 1 Current Nutrition Reports : 132 -141.
Yang, F., Wang, L.K., Li, X., Wang, L.W., Han, X.Q. and Gong, Z.J., 2014. Sodium butyrate protects against toxin-induced acute liver failure in rats. Hepatobiliary and Pancreatic Diseases International 13: 309-315.
'Sodium butyrate protects against toxin-induced acute liver failure in rats ' () 13 Hepatobiliary and Pancreatic Diseases International : 309 -315.
Zhang, L.T., Yao, Y.M., Lu, J.Q., Yan, X.J., Yu, Y. and Sheng, Z.Y., 2007. Sodium butyrate prevents lethality of severe sepsis in rats. Shock 27: 672-677.
'Sodium butyrate prevents lethality of severe sepsis in rats ' () 27 Shock : 672 -677.
Zhou, J., Chai, F., Lu, G., Hang, G., Chen, C., Chen, X. and Shi, J., 2013. TREM-1 inhibition attenuates inflammation and tumor within the colon. International Immunopharmacology 17: 155-161.
'TREM-1 inhibition attenuates inflammation and tumor within the colon ' () 17 International Immunopharmacology : 155 -161.
| Insgesamt | Letzte 365 Tage | In den letzten 30 Tagen | |
|---|---|---|---|
| Aufrufe von Kurzbeschreibungen | 978 | 340 | 34 |
| Gesamttextansichten | 90 | 22 | 0 |
| PDF-Downloads | 49 | 12 | 0 |
Butyrate acts as energy source for intestinal epithelial cells and as key mediator of several immune processes, modulating gene expression mainly through histone deacetylation inhibition. Thanks to these effects, butyrate has been proposed for the treatment of many intestinal diseases. Aim of this study was to investigate the effect of butyrate on the expression of a large series of target genes encoding proteins involved in pro-inflammatory pathways. We performed quantitative real-time-PCR analysis of the expression of 86 genes encoding proteins bearing to pro-inflammatory pathways, before and after butyrate exposure, in primary epithelial cells derived from human small intestine and colon. Butyrate significantly down-regulated the expression of genes involved in inflammatory response, among which nuclear factor kappa beta, interferon-gamma, Toll like 2 receptor and tumour necrosis factor-alpha. Further confirmations of these data, including studies at protein level, would support the use of butyrate as effective therapeutic strategy in intestinal inflammatory disorders.
| Insgesamt | Letzte 365 Tage | In den letzten 30 Tagen | |
|---|---|---|---|
| Aufrufe von Kurzbeschreibungen | 978 | 340 | 34 |
| Gesamttextansichten | 90 | 22 | 0 |
| PDF-Downloads | 49 | 12 | 0 |